FDA Type A Meeting Scheduled for Tabelecleucel BLA Following Complete Response Letter

summarizeSummary

Atara Biotherapeutics announced that a Type A meeting with the FDA has been scheduled to discuss the Complete Response Letter for its tabelecleucel BLA, a key step towards potential resubmission.

check_boxKey Events

• FDA Type A Meeting Scheduled

  Atara Biotherapeutics announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Complete Response Letter (CRL) for the EBVALLO™ Biologics License Application (BLA) issued on January 9, 2026.

• Addressing CRL Points for Resubmission

  The company's partner, Pierre Fabre Pharmaceuticals, with Atara's support, will meet with the FDA to collaboratively address the points from the CRL and enable a resubmission with additional efficacy data.

• Regulatory Update Anticipated

  Atara's President and CEO, Cokey Nguyen, expressed optimism about gaining clarity on a path forward for BLA resubmission and anticipates providing a further regulatory update in the second quarter of 2026.

auto_awesomeAnalysis

Atara Biotherapeutics announced that a Type A meeting with the FDA has been scheduled to discuss the Complete Response Letter (CRL) for its tabelecleucel (tab-cel) Biologics License Application (BLA). This follows the company's previous disclosure on March 3, 2026, regarding the request for such a meeting. The scheduling of this meeting is a critical step forward for the company and its partner, Pierre Fabre Pharmaceuticals, as it provides a defined path to address the FDA's concerns and potentially resubmit the BLA. For a small biotech, progress in regulatory discussions after a CRL is a significant de-risking event, offering clarity on the path to market.